Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1993 1
1998 1
1999 3
2000 2
2001 2
2002 1
2007 1
2008 4
2009 2
2010 5
2011 2
2012 3
2013 1
2014 7
2015 1
2016 1
2017 2
2018 2
2019 1
2020 1
2021 2
2022 2
2023 3
2024 3
2025 4
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of ABBV-3373, a Novel Anti-Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody-Drug Conjugate, in Adults with Moderate-to-Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double-Blind, Active-Controlled Proof-of-Concept Phase IIa Trial.
Buttgereit F, Aelion J, Rojkovich B, Zubrzycka-Sienkiewicz A, Chen S, Yang Y, Arikan D, D'Cunha R, Pang Y, Kupper H, Radstake T, Amital H. Buttgereit F, et al. Among authors: rojkovich b. Arthritis Rheumatol. 2023 Jun;75(6):879-889. doi: 10.1002/art.42415. Epub 2023 Apr 2. Arthritis Rheumatol. 2023. PMID: 36512671 Clinical Trial.
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
Fisher BA, Mariette X, Papas A, Grader-Beck T, Bootsma H, Ng WF, van Daele PLA, Finzel S, Noaiseh G, Elgueta S, Hermann J, McCoy SS, Akpek E, Bookman A, Sopala M, Montecchi-Palmer M, Luo WL, Scheurer C, Hueber W; TWINSS study group. Fisher BA, et al. Lancet. 2024 Aug 10;404(10452):540-553. doi: 10.1016/S0140-6736(24)01211-X. Epub 2024 Jul 31. Lancet. 2024. PMID: 39096929 Clinical Trial.
B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment.
Agmon-Levin N, Ignatenko S, Gordienko A, Cortés-Hernández J, Narongroeknawin P, Romanowska-Próchnicka K, Shen N, Ciferská H, Kodera M, Cheng-Chung WJ, Leszczynski P, Lan JL, Mysler E, Wojciechowski R, Tarr T, Vishneva E, Chen YH, Kaneko Y, Finzel S, Hoi A, Okada M, Koolvisoot A, Lee SS, Lie D, Kaneko H, Rojkovich B, Sun L, Zotkin E, Viallard JF, López BPM, Ghanshani SA, Lau C, Avrameas A, Sips C, Oliver SJ. Agmon-Levin N, et al. Among authors: rojkovich b. Ann Rheum Dis. 2025 Dec 5:S0003-4967(25)04547-9. doi: 10.1016/j.ard.2025.11.015. Online ahead of print. Ann Rheum Dis. 2025. PMID: 41353079 Free article.
Autoantibodies against complement factor B in rheumatoid arthritis.
Matola AT, Fülöp A, Rojkovich B, Nagy G, Sármay G, Józsi M, Uzonyi B. Matola AT, et al. Among authors: rojkovich b. Front Immunol. 2023 Feb 20;14:1113015. doi: 10.3389/fimmu.2023.1113015. eCollection 2023. Front Immunol. 2023. PMID: 36891314 Free PMC article.
55 results